CAJ | 학술논문

目的探讨多肿瘤标志物蛋白芯片中糖链抗原CA19-9水平升高的临床诊断意义.方法收集可供分析的25 076例多肿瘤蛋白芯片检测结果,分析CA19-9水平在各人群、各肿瘤组织中升高情况.结果恶性肿瘤患者CA19-9水平升高发生率明显高于良性病变患者及正常体检者,且胰腺癌发生率最高(62.04%),其次为肝癌(44.25%)、胃癌(26.40%)、结直肠癌(26.32%);CA19-9伴随升高的指标以CA242最为常见,其次为CEA、CA125;CA19-9/CA242、CA19-9/CEA伴随升高最常见于结直肠癌(90.00%,86.45%);CA19-9/CA125伴随升高最常见于肺癌(71.66%).CA19-9+CA242+CA125联合升高最常见于胰腺癌(54.91%);CA19-9+CA242+CEA联合升高最常见于结直肠癌(81.61%);CA19-9+AFP+CA125联合升高最常见于肝癌(32.14%);CA19-9+CEA+CA125联合升高最常见于肺癌(55.56%).结论 CA19-9在恶性肿瘤中广泛表达,但并非恶性肿瘤的特异性指标.CA19-9单项指标升高对消化系统肿瘤具有较高的诊断价值,尤其对胰腺癌,而CA19-9伴随CA125、CA19-9、CA242水平升高,有助于提高各肿瘤诊断阳性率,降低误诊率.
목적 탐토다종류표지물단백심편중당련항원CA19-9수평승고적림상진단의의.방법 수집가공분석적25 076례다종류단백심편검측결과,분석CA19-9수평재각인군、각종류조직중승고정황.결과 악성종류환자CA19-9수평승고발생솔명현고우량성병변환자급정상체검자,차이선암발생솔최고(62.04%),기차위간암(44.25%)、위암(26.40%)、결직장암(26.32%);CA19-9반수승고적지표이CA242최위상견,기차위CEA、CA125;CA19-9/CA242、CA19-9/CEA반수승고최상견우결직장암(90.00%,86.45%);CA19-9/CA125반수승고최상견우폐암(71.66%).CA19-9+CA242+CA125연합승고최상견우이선암(54.91%);CA19-9+CA242+CEA연합승고최상견우결직장암(81.61%);CA19-9+AFP+CA125연합승고최상견우간암(32.14%);CA19-9+CEA+CA125연합승고최상견우폐암(55.56%).결론 CA19-9재악성종류중엄범표체,단병비악성종류적특이성지표.CA19-9단항지표승고대소화계통종류구유교고적진단개치,우기대이선암,이CA19-9반수CA125、CA19-9、CA242수평승고,유조우제고각종류진단양성솔,강저오진솔.